News|Articles|April 4, 2024

Increasing Legislative Changes May Mark Turning Point in US Biosimilar Adoption

Clinicians advocate for an at-parity approach to biosimilars, in which they, their patients, and the local market would have the freedom to choose the product that best suits their needs.

One of the most recurrent themes within the biosimilar industry revolves around the continued approval and introduction of adalimumab (Humira) biosimilars. Presently, despite the availability of 10 adalimumab biosimilars in the market, they collectively hold less than 2% market share, although most are priced substantially lower than the reference product.¹